Cutaneous ulceration is the most common complication of infantile hemangiomas (IHs) seen in a pediatric dermatology practice.
Objective:
The most effective treatments in our experience are compared to those in the current literature.
Methods:
The study was a retrospective chart review of therapy of 169 ulcerated IHs at a tertiary care pediatric hospital and a literature review.
Results:
Combination therapy was the rule. Local wound care was required in all, pain management in 72%, pulsed dye laser in 42%, infection control in 38%, diminution of the hemangioma through systemic therapy in 36%, and suppression of bleeding in 2%.
Limitations:
A retrospective review compared to a case-control study has inherent bias. In addition, our cases were all at a tertiary referral center.
Conclusion:
All ulcerated IHs benefit from local barrier creams or dressings. Pulsed dye laser, antibiotics, topical morphine 0.1% in hydrogel, topical becaplermin, and, most importantly, systemic therapy (especially propranolol) to reduce the hemangioma may be useful.
Get full access to this article
View all access options for this article.
References
1.
HaggstromANDroletBABaselgaE. Prospective study of infantile hemangiomas: Clinical characteristics predicting complications and treatment. Pediatrics2006;118:882–7, doi:10.1542/ peds.2006-0413.
ChamlinSLHaggstromANDroletBA. Multicenter prospective study of ulcerated hemangiomas. J Pediatr2007;151: 684–9, doi:10.1016/j.jpeds.2007.04.055.
4.
HermansDJJBoezemanJBMVan de KerkhofPCM. Differences between ulcerated and non-ulcerated hemangiomas, a retrospective study of 465 cases. Eur J Dermatol2009;19:152–6.
5.
KimHJColomboMFriedenIJ. Ulcerated hemangiomas: Clinical characteristics and response to therapy. J Am Acad Dermatol2001; 44:962–72, doi:10.1067/mjd.2001.112382.
6.
MetzBJRubensteinMCLevyMLMetryDW. Response of ulcerated perineal IH of infancy to becaplermin gel, a recombinant human platelet-derived growth factor. Arch Dermatol2004;140: 867–70, doi:10.1001/archderm.140.7.867.
7.
LapidothMBen-AmitaiDBhandarkarS. Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol2009;60:350–1, doi:10.1016/j.jaad.2008.10.034.
8.
EnjolrasOBreviereGMRogerG. Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr2004;11:99–107, doi:10.1016/j.arcped.2003.10.014.
9.
EzekowitzRAMullikenJBFolkmanJ. Interferon alfa-2a therapy for life-threatening IH of infancy. N Engl J Med1992;326:1456–63, doi:10.1056/NEJM199205283262203.
10.
YanAC. Pain management for ulcerated hemangiomas. Pediatr Dermatol2008;25:585–6, doi:10.1111/j.1525-1470.2008.00781_2.x.
11.
TranQNFancherT. Achieving analgesia for painful ulcers using topically applied morphine gel. J Support Oncol2007;5: 289–93.
12.
ZeppetellaGRibeiroMD. Morphine in Intrasite gel applied topically to painful ulcers. J Pain Symptom Manage2005;29:118–9, doi:10.1016/j.jpainsymman.2004.12.006.
13.
RibeiroMDJoelSPZeppetellaG. The bioavailability of morphine applied topically to cutaneous ulcers. J Pain Symptom Manage2004;27:434–9, doi:10.1016/j.jpainsymman.2003.09.011.
14.
JansenMMvan der HorstJCvan der ValkPG. Pain-relieving properties of topically applied morphine on arterial leg ulcers: A pilot study. J Wound Care2009;18:306–11.
15.
Van IngenILJansenMMBarreraP. Topical opioids for painful ulcers in systemic sclerosis. Ann Rheum Dis2008;67:427, doi:10. 1136/ard.2007.076224.
16.
ZeppetellaGPorzioGAielliF. Opioids applied topically to painful cutaneous malignant ulcers in a palliative care setting. J Opioid Manag2007;3:161–6.
17.
AshfieldT. The use of topical opioids to relieve pressure ulcer pain. Nurs Stand2005;19:90–2.
18.
BallasSK. Treatment of painful sickle cell leg ulcers with topical opioids. Blood2002;99:1096, doi:10.1182/blood.V99.3.1096.
19.
FarleyP. Should topical opioid analgesics be regarded as effective and safe when applied to chronic cutaneous lesions?J Pharm Pharmacol2011;63:747–56, doi:10.1111/j.2042-7158.2011.01252.x.
20.
RookJMHasanWHMcCarsonKE. Temporal effects of topical morphine application on cutaneous wound healing. Anesthesiology2008;109:130–6, doi:10.1097/ALN.0b013e31817b5ac3.
21.
PandeyAGangopadhyayANSharmaSP. Conservative management of ulcerated haemangioma – twenty years experience. Int Wound J2009;6:59–62, doi:10.1111/j.1742-481X.2008.00562.x.
22.
Saint-JeanMLéauté-LabrèzeCMazereeuw-HautierJ. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol2011;64:827–32, doi:10.1016/j.jaad.2010.12.040.
23.
NaouriMSchillTMaruaniA. Successful treatment of ulcerated haemangioma with propranolol. J Eur Acad Dermatol Venereol2010;24:1109–12.
PowellJBlouinMMDavidMDuboisJ. Bleeding in congenital hemangiomas: Crusting as a clinical predictive sign and usefulness of tranexamic acid. Pediatr Dermatol2012;29:182–5.
28.
HermansDJJvan BeynumIMKoolLJS. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: A study of 20 cases with matched historical controls. J Am Acad Dermatol2011;64:833–8, doi:10.1016/j.jaad.2011.01.025.
29.
ShinHTOrlowSJChangMW. Ulcerated haemangioma of infancy: A retrospective review of 47 patients. Br J Dermatol2007; 156:1050–2, doi:10.1111/j.1365-2133.2007.07771.x.
30.
WananukulSChatproedpraiS. Ulcerated hemangiomas: Clinical features and management. J Med Assoc Thai2002;85:1220–5.
31.
KimLHCHogelingMWargonO. Propranolol: Useful therapeutic agent for the treatment of ulcerated infantile hemangiomas. J Pediatr Surg2011;46:759–63, doi:10.1016/j.jped-surg.2011.01.012.
32.
MichelJLPaturalH. Response to oral propranolol therapy for ulcerated hemangiomas in infancy. Arch Pediatr2009;16:1565–8, doi:10.1016/j.arcped.2009.09.008.
33.
DavidLRMalekMMArgentaLC. Efficacy of pulse dye laser therapy for the treatment of ulcerated hemangiomas: A review of 78 patients. Br J Plast Surg2003;56:317–27, doi:10.1016/S0007-1226 (03)00152-8.
34.
StorchCHHoegerPH. Propranolol for infantile haemangiomas: Insights into the molecular mechanisms of action. Br J Dermatol2010;163:269–74, doi:10.1111/j.1365-2133.2010.09848.x.
35.
MaguinessSMFriedenIJ. Current management of infantile hemangiomas. Semin Cutan Med Surg2010;29:106–14, doi:10. 1016/j.sder.2010.03.009.
36.
Léauté-LabrèzeCDumas de la RoqueEHubicheT. Propranolol for severe hemangiomas of infancy. N Engl J Med2008;358:2649–51, doi:10.1056/NEJMc0708819.
37.
HongEFischerG. Propranolol for recalcitrant ulcerated hemangioma of infancy. Pediatr Dermatol2011 Aug 19. DOI: 10.1111/j.1525-1470.2011.01547.x. [Epub ahead of print]
38.
ChimHArmijoBSMillerE. Propanolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. Ann Surg2012;256:146–56.
39.
LawleyLPSiegfriedEToddJL. Propranolol treatment for hemangioma of infancy: Risks and recommendations. Pediatr Dermatol2009;26:610–4, doi:10.1111/j.1525-1470.2009.00975.x.
40.
PavlakovicHKietzSLauererP. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics2010;126:e1589–93, doi:10.1542/peds.2010-0077.
41.
HollandKEFriedenIJFrommeltPC. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol2010;146:775–8, doi:10.1001/archdermatol.2010.158.
